Baricitinib retention rate: ‘real-life’ data from a mono-centric cohort of patients affected by rheumatoid arthritis

Frontiers in Medicine

Medicine

Alessandra Cartocci¹  Luca Cantarini²  Stefano Gentileschi²  Bruno Frediani²  Roberto D’Alessandro²  Marco Bardelli²  Marta Fabbroni²  Caterina Baldi²  Emilio D’Ignazio²  Paolo Falsetti²  Edoardo Conticini²  Virginia Berlengiero² 

[1] Department of Medical Biotechnologies, University of Siena, Siena, Italy;Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy;

关键词: rheumatoid arthritis;    baricitinib;    retention rate;    treatment;    real-life;    JAK inhibitors;   

DOI  :  10.3389/fmed.2023.1176613

 received in 2023-02-28, accepted in 2023-06-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectivesThe aim of this retrospective study was to evaluate baricitinib retention rate in patients affected by rheumatoid arthritis. Secondary aims were to compare the impact on treatment persistence of monotherapy and other variables such as systemic corticosteroid use, line of treatment, disease duration, sex, biomarkers positivity, and Herpes Zoster virus infection.Materials and methodsPatients with Rheumatoid Arthritis undergoing baricitinib were consecutively enrolled. Rheumatoid Arthritis diagnosis was performed with 2010 ACR/EULAR classification criteria. The cohort’s demographic, clinical and therapeutical data were retrospectively collected. The whole follow-up duration was 104 weeks.ResultsNinety-five patients affected by rheumatoid arthritis and treated with baricitinib were consecutively enrolled. At the end of follow-up, the overall retention rate was 69.3%. No statistically significant difference in retention rate was observed between patients treated with baricitinib in monotherapy or in combination with methotrexate (p = 0.638) while patients undergoing a steroidal treatment showed a significantly reduced treatment retention (p = 0.028). Contrarily, patients treated with baricitinib as a first-line b/tsDMARD showed higher drug retention (p = 0.002) compared to further treatment lines. Steroid employment, steroid dosage and previous treatment with bDMARDs correlated with risk of treatment discontinuation and at univariate analysis (p = 0.028, p < 0.001, and p = 0.002 respectively). Multivariate analysis confirmed significance for higher steroid dosage and previous treatment with bDMARDs (p = 0.002 and p = 0.046). No adverse events such as deep venous thrombosis, pulmonary embolism or tubercular infection/reactivation were reported during the study observation.ConclusionOur data show a good baricitinib retention rate after 12 and 24 months of observation (75.1 and 69.3%, respectively). In our cohort, concomitant treatment with methotrexate did not influence treatment persistence while retention was reduced in patients undergoing a steroidal treatment and/or in multi-failure subjects.

【 授权许可】

Unknown   
Copyright © 2023 Baldi, Berlengiero, Falsetti, Cartocci, Conticini, D’Alessandro, D’Ignazio, Bardelli, Fabbroni, Cantarini, Frediani and Gentileschi.